MS4A10 Inhibitors
MS4A10 inhibitors encompass a diverse array of compounds that influence various signaling pathways and cellular processes,which are indirectly involved in the regulation and functional activity of MS4A10. Among these, EGFR inhibitors like Gefitinib act by blocking EGFR signaling pathways known to regulate the expression and function of various membrane proteins, potentially including MS4A10. The inhibition of EGFR activity could lead to a decrease in MS4A10 functional activity, as EGFR is an upstream regulator in cell signaling. Similarly, PI3K inhibitors such as LY294002 and Wortmannin can indirectly influence MS4A10 by reducing AKT signaling. Since AKT is a central kinase in cellular survival and metabolism, its inhibition can alter the phosphorylation status and function of proteins like MS4A10 that may be regulated downstream.
Furthermore, mTOR inhibitors like Rapamycin can affect MS4A10 activity by modulating cellular metabolism and growth pathways that are crucial for the functional maintenance of various proteins. Kinase inhibitors, including Staurosporine and the Src family kinase inhibitor PP2, could reduce MS4A10 activity by decreasing the phosphorylation of proteins regulated by these kinases. MEK inhibitors such as U0126 and PD98059, as well as the ERK inhibitor SCH772984, can potentially decrease MS4A10 activity by disrupting the MAPK pathway, which is implicated in regulating a multitude of cellular responses. The p38 MAPK inhibitor SB203580 and JNK inhibitor SP600125 also potentially decrease MS4A10 activity by altering stress response pathways and cytokine production. Lastly, the proteasome inhibitor Bortezomib can indirectly inhibit MS4A10 function by affecting protein turnover and the accumulation of regulatory proteins that could inhibit pathways controlling MS4A10.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR inhibitor that blocks the epidermal growth factor receptor (EGFR) signaling pathways. MS4A10 can be influenced by changes in EGFR activity since EGFR pathways can regulate the expression and function of various MS4-family proteins. Inhibition of EGFR could lead to downregulation of MS4A10 function by reducing signaling through pathways that typically upregulate or maintain its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that impedes the phosphatidylinositol 3-kinase (PI3K) pathway, which is critical for numerous cellular processes including growth and survival. By inhibiting PI3K, this compound indirectly decreases downstream AKT signaling, potentially reducing the activity of proteins regulated by AKT, such as MS4A10, by altering their phosphorylation status and function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that attenuates the mechanistic target of rapamycin (mTOR) signaling, which affects cell growth and metabolism. Downregulation of mTOR signaling can lead to reduced activity of proteins that are sensitive to the metabolic state of the cell, which could include MS4A10, by impeding processes that are required for its functional activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent kinase inhibitor that can inhibit a broad range of protein kinases. This widespread inhibition could decrease the phosphorylation and thus the activity of MS4A10 if it is regulated by kinases that are targets of staurosporine. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor that suppresses the mitogen-activated protein kinase (MAPK) pathway. As MAPK pathways regulate a multitude of cellular responses, including the activity of various membrane proteins, inhibiting MEK could result in decreased functional activity of MS4A10 by altering signaling events that control its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that specifically inhibits p38 MAPK. Inhibition of p38 MAPK can alter cytokine production and response to stress signals, potentially decreasing the activity of proteins like MS4A10 that may be modulated by these pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is another MEK inhibitor that interferes with the MAPK/ERK pathway. By inhibiting this pathway, PD98059 can reduce the phosphorylation of proteins downstream of ERK, which might include MS4A10, leading to its functional inactivation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. By blocking PI3K activity, wortmannin can reduce AKT signaling, which can have downstream effects on proteins regulated by AKT, potentially including MS4A10, and lead to their decreased activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which affects the JNK signaling pathway involved in stress responses, apoptosis, and cytokine production. Inhibition of JNK signaling could impact the activity of proteins involved in these processes, possibly resulting in diminished activity of MS4A10. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an Src family kinase inhibitor that obstructs the activity of Src family kinases. These kinases can regulate various signaling pathways, including those that might control the function or expression of MS4A10. Inhibition of Src kinases could therefore indirectly lead to reduced MS4A10 activity. | ||||||